A Fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis
Abstract The L-arginine biosynthesis pathway consists of eight enzymes that catalyse the conversion of L-glutamate to L-arginine, appears to be attractive target for anti-Tuberculosis (TB) drug discovery. Starvation of M. tuberculosis deleted for either argB or argF genes led to rapid sterilization of these strains in mice while Chemical inhibition of ArgJ with Pranlukast was also found to clear chronic M. tuberculosis infection in animal models. In this work, the ligandability of four enzymes of the pathway ArgB, ArgC, ArgD and ArgF is explored using a fragment-based approach. We reveal several hits for these enzymes validated with biochemical and biophysical assays, and X-ray crystallographic data, which in the case of ArgB were further confirmed to have on-target activity against M. tuberculosis. These results demonstrate the potential of more enzymes in this pathway to be targeted with dedicated drug discovery programmes..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
bioRxiv.org - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gupta, Pooja [VerfasserIn] |
---|
Links: |
---|
doi: |
10.1101/2021.03.12.435067 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI020126786 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI020126786 | ||
003 | DE-627 | ||
005 | 20230429093652.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210315s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.03.12.435067 |2 doi | |
035 | |a (DE-627)XBI020126786 | ||
035 | |a (biorXiv)10.1101/2021.03.12.435067 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a Gupta, Pooja |e verfasserin |4 aut | |
245 | 1 | 0 | |a A Fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract The L-arginine biosynthesis pathway consists of eight enzymes that catalyse the conversion of L-glutamate to L-arginine, appears to be attractive target for anti-Tuberculosis (TB) drug discovery. Starvation of M. tuberculosis deleted for either argB or argF genes led to rapid sterilization of these strains in mice while Chemical inhibition of ArgJ with Pranlukast was also found to clear chronic M. tuberculosis infection in animal models. In this work, the ligandability of four enzymes of the pathway ArgB, ArgC, ArgD and ArgF is explored using a fragment-based approach. We reveal several hits for these enzymes validated with biochemical and biophysical assays, and X-ray crystallographic data, which in the case of ArgB were further confirmed to have on-target activity against M. tuberculosis. These results demonstrate the potential of more enzymes in this pathway to be targeted with dedicated drug discovery programmes. | ||
700 | 1 | |a Thomas, Sherine E. |e verfasserin |4 aut | |
700 | 1 | |a Cory-Wright, James |e verfasserin |4 aut | |
700 | 1 | |a Sebastián-Pérez, Víctor |e verfasserin |4 aut | |
700 | 1 | |a Burgess, Ailidh |e verfasserin |4 aut | |
700 | 1 | |a Cattermole, Emma |e verfasserin |4 aut | |
700 | 1 | |a Meghir, Clio |e verfasserin |4 aut | |
700 | 1 | |a Abell, Chris |e verfasserin |4 aut | |
700 | 1 | |a Coyne, Anthony G. |e verfasserin |4 aut | |
700 | 1 | |a Jacobs, William R. |e verfasserin |4 aut | |
700 | 1 | |a Blundell, Tom L. |e verfasserin |4 aut | |
700 | 1 | |a Tiwari, Sangeeta |e verfasserin |4 aut | |
700 | 1 | |a Mendes, Vítor |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Dez. |
773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.csbj.2021.06.006 |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.03.12.435067 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 15 |c 12 | ||
953 | |2 045F |a 570 |